A medic by trade, Mark Kotter has always held a particular interest in neuroscience and stem cell research.As founder and CEO of bit.bio, he's overseen the development of a unique approach to "reprogram" stem cells and change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's Alzheimer's, and ALS.Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.Show Notes 

Stem Cells for Drug Discovery 

Building a Stable of Stem Cells 

Conversations in Science With Disruptors Leading the Way 

Neuroscience | Charles River 

bit.bio 
Resources 

https://www.bit.bio/news/focus-on-a-founder-with-mark-kotter-celebrating-10-years-of-community 

https://www.criver.com/eureka/podcast/e28-building-the-building-blocks-of-life  

https://www.criver.com/about-us/disruptors/meet-mark?region=3601 

https://www.bit.bio/ 

Stem Cells for Drug Discovery 
Next Generation Reprogramming of Human iPSCs to Generate Disease-specific Glutamatergic Neurons Carrying HTT Gene for Huntington’s Disease Research and Drug Discovery https://www.criver.com/neuroscience-2021